Securities code: Berry Genomics Co.Ltd(000710) securities abbreviation: Berry Genomics Co.Ltd(000710) Announcement No.: 2022022 Berry Genomics Co.Ltd(000710)
Announcement on the forecast of daily connected transactions in 2022
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Berry Genomics Co.Ltd(000710) (hereinafter referred to as ” Berry Genomics Co.Ltd(000710) “, “company” and “listed company”) held the 16th meeting of the ninth board of directors on April 14, 2022, deliberated and adopted the proposal on the prediction of daily connected transactions in 2022, as follows:
1、 Basic information of daily connected transactions
(I) overview of daily connected transactions
1. The company expects to act as an agent for tumor related products and services of Fujian Herui Gene Technology Co., Ltd. (hereinafter referred to as “Fujian Herui”) in 2022. The total amount of such related party transactions is expected to be 10 million yuan, and the actual amount of similar transactions in 2021 is 267663 million yuan.
2. The company expects to sell Fujian Herui tumor related products and services (including but not limited to sequencing equipment, sequencing reagents and other related reagents, sequencing services) in 2022. The total amount of such related party transactions is expected to be 60 million yuan, and the actual amount of similar transactions in 2021 is 713055 million yuan.
3. The proposal on the prediction of daily connected transactions in 2022 will take effect after being reviewed and approved by the board of directors. The connected directors Mr. Zhou Daixing, Mr. Wang Junfeng and Ms. Wang Hongxia need to avoid voting, and the independent directors need to express their prior and independent opinions on the proposal. (II) estimated category and amount of daily connected transactions
Amount of related party transactions and related party contracts as of the disclosure date in the previous year related party transactions content related party transactions pricing principle amount or estimated amount of related party transactions (10000 yuan)
Amount (10000 yuan) (10000 yuan)
Fujian hecong bereki
Equipment and reagents purchased by Herui
Gene reagents and other equivalent products to related persons, if they are exported
For the sale of obstetric technology, it shall be subject to the agreement signed by both parties 04 647. sixteen
Pricing in the distribution agreement of products, commodities and limited customs reagents;
If the company is used for its own business
The development of subtotal is through network 3 Anhui Fengyuan Pharmaceutical Co.Ltd(000153) 04 153. 04
Fujian network information, telephone consultation
And Switzerland won the country by means of bidding
The price of similar products in the gene,
The sequencing service provided by science and technology is priced at 3 Chongqingyukaifaco.Ltd(000514) at the market price 66 6,483.34
Limited evidence to related parties; Fujian Herui from Beirui
Provide gene procurement and sequencing services for labor companies,
According to the agreement signed by both parties
Subtotal cancellation agreement or project confirmation 3 Chongqingyukaifaco.Ltd(000514) 66 514. sixty-six
Pricing agreement and service agreement
Fujian
Herui according to Berry Genomics Co.Ltd(000710) Hefu
Accept the purchase of related genes, tumor detection, and the sales contract signed by Jianhe Ruili
Scientific and technological services / reagent consumables provided by 1000169 50 2,676.63
Labor service limited agreement or purchase agreement
Company price
Subtotal 1000169 50 2,676.63
Total 7 Qinchuan Machine Tool & Tool Group Share Co.Ltd(000837) 20 9,807.13
(III) actual occurrence of daily related party transactions in the previous year
Actual amount of related party transactions estimated amount of actual amount of related party transactions accounted for the disclosure date of actual occurrence and related party transactions (10000 yuan) (10000 yuan) of related party transactions (estimated amount and estimated index
Easy content (amount) proportion amount difference
Sales equipment
Report to related Fujian Hebei and survey
Human gene sequencing reagent
Technology and others 647.16200032.36% – 67.64%
Products, related trials of the Company Limited, April 29, 2021, commodity agent, spring tide
Subtotal information network, announcement 647.16200032.36% – 67.64% No.:
To associate Fujian and
Rui gene test 2021031
People provide scientific and technological orderly services 6483341200054.03% – 45.97%
Labor Service Co., Ltd
Subtotal 6483341200054.03% – 45.97%
Accept customs clearance and procurement
Detection of human tirui gene tumor
Science and technology has 2676631000267 66% 167.66%
Services provided by labor limited companies
Subtotal of services
2,676.63 1,000 267. 66% 167.66%
Total 980713-34.62%
The difference between the actual total amount and the estimated total amount in 2021 is mainly due to the fact that Fujian Herui hepatoma screening products – “lesning” has entered the commercial transformation stage, and the procurement of relevant project sequencing and equipment from the company has gradually decreased, superimposing the impact of repeated covid-19 epidemic on the development of daily business, The difference between the actual total amount and the estimated total amount is based on the actual operation of both parties.
2、 Introduction of related persons and related relationship
(I) basic information
Name of related party: Fujian Herui Gene Technology Co., Ltd
Legal representative: Zhou Jun
Registered capital: 8854044 million yuan
Main business: general projects: medical research and experimental development; Research and development of biochemical product technology; Software development; Information technology consulting services; Biomass energy resource database information system platform; Data processing and storage support services; Digital content production services (excluding publishing and distribution); Rental services (excluding publication rental); Sales of chemical products (excluding licensed chemical products); Non residential real estate leasing; Sales of class II medical devices; Production of class I medical devices; Engineering and technical research and experimental development (except for projects subject to approval according to law, carry out business activities independently according to law with business license): medical services; Class III medical device business; Import and export of goods; Technology import and export; Production of class II medical devices; Class III medical device production (for items that must be approved according to law, business activities can be carried out only after being approved by relevant departments. The specific business items shall be subject to the approval documents or licenses of relevant departments)
Address: R & D building 7, No. 33, Donghu Road, digital Fujian Industrial Park, Changle District, Fuzhou
Latest financial data (Unaudited):
Project amount (unit: RMB)
December 31, 2021
Total assets 82010448390
Net assets 55329420531
January December 2021
Main business income 16090857625
Operating profit -30326189768
Net profit -30576062684
(II) relationship with listed companies
Berry Genomics Co.Ltd(000710) directors Mr. Zhou Daixing, Ms. Wang Hongxia and Mr. Wang Junfeng also serve as directors in Fujian Herui. The above-mentioned relationship complies with the provisions of the stock listing rules. Mr. Zhou Daixing, Ms. Wang Hongxia and Mr. Wang Junfeng have avoided voting when the board of directors deliberated the proposal on the prediction of daily connected transactions in 2022.
(III) performance capability analysis
On November 17, 2017 and December 15, 2017, the company was on cninfo.com（ http://www.cn.info.com.cn. ）The announcement on abandoning the preemptive right to increase capital and shares of subsidiaries and related party transactions (Announcement No.: 2017080) and the supplementary announcement on abandoning the preemptive right to increase capital and shares of subsidiaries and related party transactions (Announcement No.: 2017085) were disclosed respectively. Fujian Herui has obtained a capital increase of RMB 800 million from well-known venture capital institutions, and conducted a + round of financing in 2020 and B round of financing in 2021, The introduction of investors with a complex industry background will expand business channels by virtue of the industrial advantages of shareholders. At the same time, venture capital institutions have strong risk tolerance, financial strength and rich investment experience, which will help Fujian and Switzerland obtain financial guarantee for the development of tumor business and avoid potential risks. The liver cancer early screening product “laisining” formed by the “national multi center, prospective 10000 person cohort liver cancer very early warning marker screening project (precar project)” jointly organized by Fujian, Ruihe and the national liver cancer science center has been commercialized. At the same time, it has actively promoted the application of registered products of “early warning and early diagnosis kit and related equipment research and development of liver cancer related to viral hepatitis”.
Fujian Herui can abide by the contract in the development of tumor business, with good credit, normal operation and performance ability.
3、 Main contents of related party transactions
(I) main pricing basis of related party transactions
1. The company acts as an agent for Fujian Herui tumor related products and services
